GSK Plc (GSK)
49.51
+0.49
(+1.00%)
USD |
NYSE |
Oct 16, 16:00
49.50
0.00 (0.00%)
After-Hours: 20:00
GSK Cash from Investing (Quarterly) : -1.176B for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.176B |
| March 31, 2026 | -1.784B |
| December 31, 2025 | -3.184B |
| September 30, 2025 | -2.152B |
| June 30, 2025 | -823.69M |
| March 31, 2025 | -1.580B |
| December 31, 2024 | -1.509B |
| September 30, 2024 | -952.61M |
| June 30, 2024 | 924.65M |
| March 31, 2024 | -254.86M |
| December 31, 2023 | 292.18M |
| September 30, 2023 | -669.67M |
| June 30, 2023 | -1.331B |
| March 31, 2023 | -684.07M |
| December 31, 2022 | -385.03M |
| September 30, 2022 | -5.005B |
| June 30, 2022 | -583.22M |
| March 31, 2022 | -4.818B |
| December 31, 2021 | -472.10M |
| September 30, 2021 | -1.650B |
| June 30, 2021 | -273.42M |
| March 31, 2021 | -67.57M |
| December 31, 2020 | -42.44M |
| September 30, 2020 | -717.14M |
| June 30, 2020 | 3.554B |
| Date | Value |
|---|---|
| March 31, 2020 | -111.16M |
| December 31, 2019 | -408.20M |
| September 30, 2019 | -544.16M |
| June 30, 2019 | -758.83M |
| March 31, 2019 | -5.177B |
| December 31, 2018 | -520.62M |
| September 30, 2018 | -311.47M |
| June 30, 2018 | -13.29B |
| March 31, 2018 | -592.81M |
| December 31, 2017 | -491.96M |
| September 30, 2017 | -601.40M |
| June 30, 2017 | -583.43M |
| March 31, 2017 | -276.33M |
| December 31, 2016 | -216.07M |
| September 30, 2016 | -229.04M |
| June 30, 2016 | -440.40M |
| March 31, 2016 | -970.28M |
| December 31, 2015 | -692.57M |
| September 30, 2015 | -276.89M |
| June 30, 2015 | -593.12M |
| March 31, 2015 | 10.66B |
| December 31, 2014 | -651.62M |
| September 30, 2014 | -382.84M |
| June 30, 2014 | -300.18M |
| March 31, 2014 | -1.685B |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| AstraZeneca PLC | -1.856B |
| Johnson & Johnson | -- |
| Eli Lilly & Co. | -15.40B |
| Merck & Co., Inc. | -5.602B |
| Novo Nordisk A/S | -2.009B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 3.386B |
| Cash from Financing (Quarterly) | -2.542B |
| Free Cash Flow | 6.621B |
| Free Cash Flow Per Share (Quarterly) | 1.236 |
| Free Cash Flow to Equity (Quarterly) | 3.434B |
| Free Cash Flow to Firm (Quarterly) | 2.892B |
| Free Cash Flow Yield | 6.55% |